"We are very encouraged by the subcutaneous Phase 1b/2a results for Amycretin in people living ... executive vice president for Development at Novo Nordisk. "The results seen in the trial support ...

Fact checked by Nick BlackmerFact checked by Nick Blackmer In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin ...

Amycretin, administered via injection, is designed to target two key hormones: GLP-1, mimicked by Novo Nordisk’s flagship obesity drug Wegovy, and amylin, which regulates hunger. The recent ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. See why NVO stock is a Buy.

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...

Results of early-stage trial of injectable amycretin Novo shares jump as much ... drugs from Eli Lilly Jan 24 (Reuters) - One of Novo Nordisk's (NOVOb.CO), opens new tab next-generation obesity ...

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...